Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder
NCT03922646 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104
Last updated 2023-08-28
Summary
Chronic drug addiction is not only associated with increased mental health symptoms, such as anxiety and depression, but also with brain (neural and cognitive) deficits. These neurocognitive deficits (NCDs) in memory, attention, decision-making, self-control and judgement disturb normal daily functioning and attempts for abstinence. These NCDs are also associated with worse long-term treatment outcomes. Current treatment programs for addiction to opioids and amphetamines are mainly focused on abstinence from illicit drugs with or without assistance of medications, with the assumption that these NCDs will subsequently heal. However, NCDs are found to persist even after a long-term abstinence and are thought to contribute to relapse, decreases quality of life, or lack of reintegration into society. Furthermore, NCDs (particularly related to attention and memory) are considered a potential obstacle for engagement in therapy services for addiction and associated mood, anxiety and trauma-related comorbidities (i.e., cognitive-behavioral therapies). Brain rehabilitation programs focused on compensatory strategies and training exercises for NCDs associated with traumatic brain injuries, stroke, multiple sclerosis and schizophrenia has consistently been found to improve functioning and long-term outcomes for these populations. There have been a few preliminary attempts to transplant cognitive rehabilitation with substance use populations, with some limited promise. However, these previous studies failed to link cognitive strategies with the drug use and affective/craving symptoms experienced by patients and also did not fully incorporate knowledge gained from neuroscientific research on opioid and/or methamphetamine addiction specifically.
The aim of this study is to characterize clinical efficacy for an intervention targeting NCDs in opioid and/or methamphetamine addiction by enhancing awareness and use of neurocognitive skills in the context of substance use recovery. This aim will be accomplished by randomizing 80 subjects with opioid and/or methamphetamine use disorder who are already enrolled in substance use treatment in the state of Oklahoma to also complete a novel "Neurocognitive Empowerment for Addiction Treatment" (NEAT) program developed by a group of investigators at Laureate Institute for Brain Research, Tulsa, Oklahoma. NEAT will be novel in (a) its use of cartoons, brain awareness games and real-life scenarios to ensure it is interactive and engaging, (b) the focus on the role of neurocognitive deficits in recovery from substance use and co-occurring mental health symptomatology, and (c) its incorporation of neuroscientific findings specific to substance use to the training and exercise strategies. Subjects will be followed up for twelve months after starting the program with different measures for addiction and mental health recovery to explore the efficacy of NEAT compared to the control intervention. Using LIBR's cutting-edge neuroimaging facilities before and after interventions, this study has the unique opportunity to monitor not only clinical outcomes but also potential changes NEAT may have on brain structure and function. In case of finding reasonable clinical efficacy for NEAT, it will be hopefully integrated as a manualized brain rehabilitation program to the substance use treatment programs.
Conditions
- Opioid-use Disorder
- Amphetamine Use Disorders
Interventions
- BEHAVIORAL
-
Neurocognitive Empowerment for Addiction Treatment (NEAT)
NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).
- BEHAVIORAL
-
Active Control
The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
Sponsors & Collaborators
-
Oklahoma Center for the Advancement of Science and Technology
collaborator OTHER -
Laureate Institute for Brain Research, Inc.
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-06
- Primary Completion
- 2022-07-28
- Completion
- 2023-05-12
Countries
- United States
Study Locations
More Related Trials
-
An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers.
NCT00628927 ·Status: COMPLETED
-
Study of Medical Treatment for Methamphetamine Addiction
NCT00833443 ·Status: COMPLETED ·Phase: PHASE2
-
Neurofeedback During Naturalistic Stimuli to Reduce Craving in Heroin Addiction
NCT07344233 ·Status: COMPLETED ·Phase: NA
-
Piracetam for Treatment of Cocaine Addiction - 3
NCT00000198 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Methamphetamine-Dependent and Healthy Volunteers Using a Web-Enabled Cognitive Neuropsychological Evaluation System
NCT01919437 ·Status: UNKNOWN ·Phase: NA
-
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
NCT03059563 ·Status: TERMINATED ·Phase: PHASE1
-
Methylphenidate to Treat Methamphetamine Dependence
NCT01044238 ·Status: UNKNOWN ·Phase: PHASE2
-
Individualized Neuromodulation of Craving Control for Meth Use Disorders
NCT06695637 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Exercise in Methamphetamine Use Disorder Upregulation and Neural Function
NCT03709667 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
NCT05610072 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Individualized Neuromodulation for the Core Clinical Features of Drug Addiction
NCT06165198 ·Status: COMPLETED ·Phase: NA
-
Targeting Drug Memories With Methylphenidate
NCT05978167 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence
NCT00385268 ·Status: COMPLETED ·Phase: PHASE2
-
Modification of Cue Reactivity by Neurofeedback in Human Addiction
NCT04366505 ·Status: UNKNOWN ·Phase: NA
-
Pharmacotherapy & CM for Opioid and Cocaine Dependence
NCT00838981 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cocaine Abuse and Attention Deficit Disorder - 3
NCT00000268 ·Status: COMPLETED ·Phase: NA
-
Brain Dopaminergic Signaling in Opioid Use Disorders
NCT03190954 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
RTI-336 as a Treatment for Methamphetamine Dependence
NCT01601717 ·Status: WITHDRAWN ·Phase: PHASE1
-
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
NCT01011829 ·Status: COMPLETED ·Phase: PHASE2
-
Neuromodulation and Cognitive Training for Substance Use Disorders
NCT04426214 ·Status: RECRUITING ·Phase: NA
-
Piracetam for Treatment of Cocaine Addiction, Phase II - 4
NCT00000199 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1
NCT00033124 ·Status: UNKNOWN ·Phase: PHASE2
-
Norepinephrine Transporter Imaging in Addiction Disorders
NCT01719458 ·Status: WITHDRAWN
-
Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project
NCT03799341 ·Status: COMPLETED ·Phase: NA
-
Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5
NCT00015223 ·Status: COMPLETED ·Phase: PHASE2